Regarding EGX358, the lack of effects in the open field and plus maze could indicate that ERβ is not involved in regulating anxiety-like behaviors among individuals with established brain amyloid, phospho-tau burden, and AD-related neurodegeneration, and may not be an effective therapy for mood-related symptoms in AD patients. The gene discussed is MAPT; the disease is Alzheimer disease.